IN2012DN02993A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02993A IN2012DN02993A IN2993DEN2012A IN2012DN02993A IN 2012DN02993 A IN2012DN02993 A IN 2012DN02993A IN 2993DEN2012 A IN2993DEN2012 A IN 2993DEN2012A IN 2012DN02993 A IN2012DN02993 A IN 2012DN02993A
- Authority
- IN
- India
- Prior art keywords
- ebv
- provides
- present
- cell
- tcr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
- C07K14/05—Epstein-Barr virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0917090.3A GB0917090D0 (en) | 2009-09-29 | 2009-09-29 | T-cell receptor |
| PCT/GB2010/001821 WO2011039508A2 (en) | 2009-09-29 | 2010-09-28 | T-cell receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN02993A true IN2012DN02993A (enExample) | 2015-07-31 |
Family
ID=41350560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2993DEN2012 IN2012DN02993A (enExample) | 2009-09-29 | 2010-09-28 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8889141B2 (enExample) |
| EP (1) | EP2483294B1 (enExample) |
| JP (2) | JP6180114B2 (enExample) |
| KR (1) | KR101760277B1 (enExample) |
| CN (1) | CN102695717B (enExample) |
| AU (1) | AU2010302477B2 (enExample) |
| ES (1) | ES2584541T3 (enExample) |
| GB (1) | GB0917090D0 (enExample) |
| IN (1) | IN2012DN02993A (enExample) |
| WO (1) | WO2011039508A2 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013502235A (ja) | 2009-08-24 | 2013-01-24 | ベイラー カレッジ オブ メディスン | 複数の腫瘍抗原または複数のウイルスに対する特異的ｃｔｌ株の作製［関連出願の相互参照］ |
| US10548921B2 (en) | 2011-04-08 | 2020-02-04 | Baylor College Of Medicine | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
| ES2858978T3 (es) | 2011-10-28 | 2021-09-30 | Regeneron Pharma | Ratones con receptores de linfocitos T genéticamente modificados |
| GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
| BR112014014591A8 (pt) | 2011-12-12 | 2017-07-04 | Baylor College Medicine | processo para a expansão in vitro de células t específicas de antígeno, produto de células t autólogas ou alogênicas expandidas, composição farmacêutica, e, método de tratamento de um paciente, e, usos de uma linhagem de células engenheirada, de células dendríticas pulsadas com misturas de antígeno-peptídeo, de t-apcs pulsadas com misturas de antígeno-peptídeo/peptídeo, e de misturas de antígeno-peptídeo com pbmcs |
| ES2928851T3 (es) | 2012-02-09 | 2022-11-23 | Baylor College Medicine | Mezclas pep para generar CTL multivíricos con amplia especificidad |
| WO2014042226A1 (ja) | 2012-09-12 | 2014-03-20 | 株式会社癌免疫研究所 | 抗原特異的ヘルパーｔ細胞レセプター遺伝子 |
| EP3572423B1 (en) | 2013-07-15 | 2023-12-06 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Anti-human papillomavirus 16 e6 t cell receptors |
| GB201314404D0 (en) * | 2013-08-12 | 2013-09-25 | Immunocore Ltd | T Cell Receptors |
| WO2015184228A1 (en) | 2014-05-29 | 2015-12-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-human papillomavirus 16 e7 t cell receptors |
| WO2015199618A1 (en) * | 2014-06-24 | 2015-12-30 | National University Of Singapore | Epstein-barr virus lmp2 specific antibody and uses thereof |
| HK1243333A1 (zh) * | 2014-10-31 | 2018-07-13 | The Trustees Of The University Of Pennsylvania | 用於修饰的t细胞的方法和组合物 |
| WO2016095783A1 (zh) * | 2014-12-17 | 2016-06-23 | 中国科学院广州生物医药与健康研究院 | 识别eb病毒短肽的t细胞受体 |
| CA2971677A1 (en) | 2014-12-23 | 2016-06-30 | Margaret Anne Brimble | Amino acid and peptide conjugates and uses thereof |
| RS64540B1 (sr) | 2015-04-06 | 2023-09-29 | Regeneron Pharma | Imunski odgovori posredovani humanizovanim t ćelijama kod ne-humanih životinja |
| CN104830793A (zh) * | 2015-05-05 | 2015-08-12 | 杨光华 | 基于lmp-1抗原的dc细胞、靶向性免疫细胞群及其制备方法和用途 |
| CA2988768A1 (en) | 2015-06-09 | 2016-12-15 | Memorial Sloan Kettering Cancer Center | T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla |
| KR101794304B1 (ko) | 2015-09-01 | 2017-11-06 | 가톨릭대학교 산학협력단 | Ｅｂｖ 항원 특이 ｔ―세포 수용체 및 이의 용도 |
| WO2017049291A1 (en) | 2015-09-18 | 2017-03-23 | Baylor College Of Medicine | Immunogenic antigen identification from a pathogen and correlation to clinical efficacy |
| GB201520191D0 (en) * | 2015-11-16 | 2015-12-30 | Cancer Rec Tech Ltd | T-cell receptor and uses thereof |
| WO2017145097A2 (en) | 2016-02-26 | 2017-08-31 | Auckland Uniservices Limited | Amino acid and peptide conjugates and conjugation process |
| KR102468453B1 (ko) * | 2016-09-19 | 2022-11-17 | 바이엘 크롭사이언스 악티엔게젤샤프트 | 농약으로서의 피라졸로[1,5-a]피리딘 유도체 |
| CN108218976B (zh) * | 2016-12-09 | 2021-11-05 | 香雪生命科学技术（广东）有限公司 | 衍生自lmp1的肿瘤抗原短肽 |
| EP3666888A4 (en) | 2017-08-10 | 2021-09-01 | Good T Cells, Inc. | T-CELL ACTIVATION METHOD FOR CANCER TREATMENT |
| WO2019195586A1 (en) | 2018-04-06 | 2019-10-10 | The Regents Of The University Of California | Methods of treating egfrviii expressing glioblastomas |
| AU2019249221A1 (en) | 2018-04-06 | 2020-10-22 | The Regents Of The University Of California | Methods of treating glioblastomas |
| JP2022512538A (ja) * | 2018-11-27 | 2022-02-07 | デューク ユニバーシティ | Ｅｂｖ関連がんの処置のための抗ｌｍｐ２ ｔｃｒ－ｔ細胞療法 |
| CN113423724B (zh) * | 2018-12-27 | 2023-11-24 | 深圳华大生命科学研究院 | Ebv表位高亲和力t细胞受体 |
| EP3786178A1 (en) | 2019-08-30 | 2021-03-03 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Tcr constructs specific for ebv-derived antigens |
| WO2021211455A1 (en) * | 2020-04-13 | 2021-10-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla class i-restricted t cell receptors against lmp2 |
| WO2021243695A1 (en) * | 2020-06-05 | 2021-12-09 | Guangdong Tcrcure Biopharma Technology Co., Ltd. | Tcr-t cell therapy targeting epstein-barr virus |
| EP3940075A1 (en) * | 2020-07-17 | 2022-01-19 | Istituto Nazionale Di Genetica Molecolare-INGM | Inhibitors of line1 and uses thereof |
| JP2024512702A (ja) | 2021-03-31 | 2024-03-19 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｔｃｒβレパートリーの改善された多様性を伴うヒト化細胞免疫系の構成要素を含む、遺伝的に改変されたマウス |
| EP4091627A1 (en) | 2021-05-21 | 2022-11-23 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Tcr constructs specific for magea4-derived epitopes |
| CN113773378B (zh) * | 2021-10-14 | 2023-11-03 | 深圳大学总医院 | T细胞受体及其应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101182531B (zh) * | 2007-11-09 | 2010-06-02 | 暨南大学 | Eb病毒特异性tcr基因相关的重组质粒及构建抗ebv特异性ctl的方法 |
-
2009
- 2009-09-29 GB GBGB0917090.3A patent/GB0917090D0/en not_active Ceased
-
2010
- 2010-09-28 CN CN201080053971.2A patent/CN102695717B/zh not_active Expired - Fee Related
- 2010-09-28 WO PCT/GB2010/001821 patent/WO2011039508A2/en not_active Ceased
- 2010-09-28 ES ES10777061.2T patent/ES2584541T3/es active Active
- 2010-09-28 JP JP2012531494A patent/JP6180114B2/ja not_active Expired - Fee Related
- 2010-09-28 US US13/498,561 patent/US8889141B2/en not_active Expired - Fee Related
- 2010-09-28 AU AU2010302477A patent/AU2010302477B2/en not_active Ceased
- 2010-09-28 KR KR1020127009216A patent/KR101760277B1/ko not_active Expired - Fee Related
- 2010-09-28 EP EP10777061.2A patent/EP2483294B1/en not_active Not-in-force
- 2010-09-28 IN IN2993DEN2012 patent/IN2012DN02993A/en unknown
-
2015
- 2015-11-09 JP JP2015219230A patent/JP2016047064A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20120244132A1 (en) | 2012-09-27 |
| GB0917090D0 (en) | 2009-11-11 |
| AU2010302477A1 (en) | 2012-04-19 |
| JP2016047064A (ja) | 2016-04-07 |
| KR20120074291A (ko) | 2012-07-05 |
| EP2483294B1 (en) | 2016-07-13 |
| JP6180114B2 (ja) | 2017-08-16 |
| JP2013505734A (ja) | 2013-02-21 |
| US8889141B2 (en) | 2014-11-18 |
| ES2584541T3 (es) | 2016-09-28 |
| KR101760277B1 (ko) | 2017-07-21 |
| WO2011039508A3 (en) | 2011-06-30 |
| CN102695717B (zh) | 2016-08-10 |
| EP2483294A2 (en) | 2012-08-08 |
| WO2011039508A2 (en) | 2011-04-07 |
| AU2010302477B2 (en) | 2017-01-19 |
| CN102695717A (zh) | 2012-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN02993A (enExample) | ||
| ZA202006432B (en) | T cell receptors | |
| NZ610267A (en) | A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use | |
| PH12016500272A1 (en) | T cell receptors | |
| MX2022005922A (es) | Receptores de tcr de prame y usos de estos. | |
| NZ600732A (en) | Oxyntomodulin peptide analogue | |
| GB201206559D0 (en) | Polypeptide | |
| NZ598356A (en) | Antigenic tau peptides and uses thereof | |
| HRP20240676T1 (hr) | Proteini domena skele na bazi fibronektina koji vezuju miostatin | |
| WO2013151672A3 (en) | Modified polynucleotides for the production of oncology-related proteins and peptides | |
| NZ706884A (en) | Fc gamma receptor iib variants | |
| JP2017514522A5 (enExample) | ||
| MX2015003310A (es) | Moleculas de union il-17a novedosas y usos medicos de las mismas. | |
| MX377650B (es) | Vacuna y métodos para reducir una infección por campylobacter. | |
| NZ705899A (en) | Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (trem-1) trem-like transcript 1 (tlt-1) and uses thereof | |
| NZ599590A (en) | Factor involved in latent infection with herpesvirus, and use thereof | |
| NZ629309A (en) | Tumour necrosis factor receptor fusion proteins and methods of using the same | |
| MX2009007261A (es) | Vacuna de peptido foxp3. | |
| NZ586074A (en) | LCLRP peptides, constructs and uses thereof | |
| Koh et al. | Degradation-resistant protein domains limit host cell processing and immune detection of mycobacteria | |
| MX2010005816A (es) | Epítopos de péptido de stat3. | |
| JP2015527074A5 (enExample) | ||
| NZ603611A (en) | Insulin-like growth factor 1 receptor binding peptides | |
| PH12013501105A1 (en) | Tomm34 peptides and vaccines including the same | |
| MX2013007007A (es) | Vacunas a base de peptidos de la proteina c5a de complemento. |